Amrad, Ludwig beef up agreement
Wednesday, 03 November, 2004
Amrad (ASX:AML) and the Ludwig Institute for Cancer Research have strengthened their collaboration for the development of vascular endothelial growth factor B (VEGF-B), which has potential applications in cancer and cardiovascular disease.
Under the agreement, the partners will coordinate research, development and commercialisation activities to appropriately leverage the combined expertise of the two groups. Intellectual property generated since the original agreement was reached will also be brought together.
Amrad is developing antibodies against VEGF-B for evaluation as potential cancer treatments, in addition to evaluating VEGF-B in coronary disease models. Ludwig researchers in Sweden and Finland will work closely with Amrad to move therapies based on VEGF-B into the clinic as soon as possible.
Noxopharm says paper reveals science behind its immune system platform
Clinical-stage Australian biotech company Noxopharm Limited says a Nature Immunology...
Neurosensing/neurostimulation implants session to be held on Monday
On Monday, a session at UNSW Sydney will include people who are benefiting from bioelectronics...
argenx and Monash University partner against autoimmune diseases
To advance a pioneering molecule for autoimmune diseases, global immunology company argenx has...
